<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019496</url>
  </required_header>
  <id_info>
    <org_study_id>BB168/18</org_study_id>
    <nct_id>NCT04019496</nct_id>
  </id_info>
  <brief_title>Neurophysiology of Prophylactic Treatment in Migraine</brief_title>
  <official_title>Neurophysiological Characterization of Treatment Response Following the Initiation of Prophylactic Therapy in Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to improve the pathophysiological understanding of migraine in in a&#xD;
      longitudinal observational study investigating changes of established neurophysiological and&#xD;
      imaging parameters in line with changes of the clinical phenotype.&#xD;
&#xD;
      The study's focus is the investigation of mechanisms that are directly related to the cyclic&#xD;
      character of migraine and its core structures. In this context, the primary endpoint is a&#xD;
      change in the nociceptive blink reflex, an established brain stem reflex to study the&#xD;
      trigemino-spinal system, associated with changes in migraine frequency and severity. In order&#xD;
      to reliably detect changes in the trigeminal pain system, investigations are performed in&#xD;
      patients before starting a prophylactic therapy and 3 months afterwards. Several secondary&#xD;
      endpoints are used to evaluate changes of multimodal sensory and cortical information&#xD;
      processing. Cerebral imaging will include examinations of structural and network effects of&#xD;
      altered migraine disease activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Actual">May 2, 2021</completion_date>
  <primary_completion_date type="Actual">May 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>nociceptive blink reflex habituation</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>habituation of the area under of the curve of the R2 blink reflex component on the side primarily affected by migraine headaches</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nociceptive blink reflex area</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>area under of the curve of the R2 blink reflex component on the side primarily affected by migraine headaches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>somatosensory evoked potentials (SSEP)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>habituation of the N20 SSEP component following bilateral median nerve stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pattern-reversal visual evoked potentials (VEP)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>habituation of the P100 VEP component following bilateral optic nerve stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>migraine headache frequency</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>days with migraine headaches during the last month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>headache impact test (HIT-6)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>impact of migraine severity on daily routine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>migraine disability assessment (MIDAS)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>impact of migraine frequency on daily routine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System Profile 29 (PROMIS-29)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>multi domain patient reported quality of life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>transcranial magnetic stimulation (TMS)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>input-output curves of motor evoked potential following single and double-pulse navigated TMS to the side stimulated during the nociceptive blink reflex examination</description>
  </other_outcome>
  <other_outcome>
    <measure>electroencephalography (EEG)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>EEG connectivity following nociceptive and sensory stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>structural magnetic resonance imaging (sMRI)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>volumetry of brain structures involved in central pain processing (e.g. cingulate cortex, insula, thalamus)</description>
  </other_outcome>
  <other_outcome>
    <measure>functional magnetic resonance imaging (fMRI)</measure>
    <time_frame>baseline and after 3 months</time_frame>
    <description>resting-state connectivity of networks involved in central pain processing</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">44</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Episodic Migraine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>equal to or less than 1 headache day/month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibodies against calcitonin-gene related peptide or its receptor</intervention_name>
    <description>the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient</description>
    <arm_group_label>Episodic Migraine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients seen in the local headache clinic are screened for eligibility to participate&#xD;
        the study. Clinical routine is not influenced by participation in this observational study,&#xD;
        importantly choice of prophylactic treatment solely depends on the physician's and&#xD;
        patient's decision based on national guidelines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (migraineurs):&#xD;
&#xD;
          -  episodic migraine according to ICHD (international classification of headache&#xD;
             disorders)-3 criteria&#xD;
&#xD;
          -  headache documented over at least 3 months through a headache calender&#xD;
&#xD;
          -  scheduled for prophylactic therapy of their migraine&#xD;
&#xD;
        Exclusion Criteria (migraineurs):&#xD;
&#xD;
          -  history of chronic migraine&#xD;
&#xD;
          -  current medication-overuse headache&#xD;
&#xD;
          -  neurological or psychiatric diagnosis other than headaches&#xD;
&#xD;
          -  chronic intake of central nervous system active drugs (antidepressants, antipsychotics&#xD;
             etc.)&#xD;
&#xD;
          -  contraindications for magnetic resonance imaging&#xD;
&#xD;
          -  contraindications for transcranial magnetic stimulation&#xD;
&#xD;
        Inclusion criteria (controls):&#xD;
&#xD;
          -  not more than 3 years younger or older than matched control&#xD;
&#xD;
          -  gender similar to matched control&#xD;
&#xD;
          -  menstrual cycle equal to matched control (if female)&#xD;
&#xD;
        exclusion criteria (controls):&#xD;
&#xD;
          -  more than 1 headache day/month&#xD;
&#xD;
          -  history of migraine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blink reflex</keyword>
  <keyword>electroencephalography</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>evoked potentials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

